SG11202101994XA - Genetically engineered hematopoietic stem cells and uses thereof - Google Patents
Genetically engineered hematopoietic stem cells and uses thereofInfo
- Publication number
- SG11202101994XA SG11202101994XA SG11202101994XA SG11202101994XA SG11202101994XA SG 11202101994X A SG11202101994X A SG 11202101994XA SG 11202101994X A SG11202101994X A SG 11202101994XA SG 11202101994X A SG11202101994X A SG 11202101994XA SG 11202101994X A SG11202101994X A SG 11202101994XA
- Authority
- SG
- Singapore
- Prior art keywords
- stem cells
- genetically engineered
- hematopoietic stem
- engineered hematopoietic
- genetically
- Prior art date
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/178—Lectin superfamily, e.g. selectins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862723993P | 2018-08-28 | 2018-08-28 | |
US201862728061P | 2018-09-06 | 2018-09-06 | |
US201962789440P | 2019-01-07 | 2019-01-07 | |
US201962809202P | 2019-02-22 | 2019-02-22 | |
PCT/US2019/048662 WO2020047164A1 (fr) | 2018-08-28 | 2019-08-28 | Cellules souches hématopoïétiques génétiquement modifiées et utilisations associées |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101994XA true SG11202101994XA (en) | 2021-03-30 |
Family
ID=67928915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101994XA SG11202101994XA (en) | 2018-08-28 | 2019-08-28 | Genetically engineered hematopoietic stem cells and uses thereof |
Country Status (12)
Country | Link |
---|---|
US (9) | US11389485B2 (fr) |
EP (1) | EP3844187A1 (fr) |
JP (1) | JP2022520138A (fr) |
KR (1) | KR20220036908A (fr) |
CN (1) | CN113423725A (fr) |
AU (1) | AU2019333104A1 (fr) |
BR (1) | BR112021003670A2 (fr) |
CA (1) | CA3110837A1 (fr) |
IL (1) | IL281113A (fr) |
MX (1) | MX2021002415A (fr) |
SG (1) | SG11202101994XA (fr) |
WO (1) | WO2020047164A1 (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019010196A (es) | 2017-02-28 | 2019-12-19 | Vor Biopharma Inc | Composiciones y métodos para la inhibición de proteínas específicas del linaje. |
CN113423725A (zh) * | 2018-08-28 | 2021-09-21 | Vor生物制药股份有限公司 | 遗传工程化造血干细胞及其用途 |
KR20220035877A (ko) * | 2019-05-23 | 2022-03-22 | 보르 바이오파마 인크. | Cd33 변형을 위한 조성물 및 방법 |
KR20220047380A (ko) * | 2019-08-28 | 2022-04-15 | 보르 바이오파마 인크. | Cll1 변형을 위한 조성물 및 방법 |
WO2021041977A1 (fr) * | 2019-08-28 | 2021-03-04 | Vor Biopharma, Inc. | Compositions et procédés pour modification de cd133 |
EP4048790A4 (fr) * | 2019-10-22 | 2024-03-27 | Fred Hutchinson Cancer Center | Réduction de l'expression de cd33 mediee par des editeurs de bases pour protéger sélectivement des cellules thérapeutiques |
WO2022047168A1 (fr) * | 2020-08-28 | 2022-03-03 | Vor Biopharma Inc. | Compositions et procédés pour modification de cll1 |
EP4204564A1 (fr) * | 2020-08-28 | 2023-07-05 | Vor Biopharma Inc. | Compositions et procédés pour modification de cd123 |
WO2022056489A1 (fr) * | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions et procédés pour la modification de cd38 |
US20230364233A1 (en) * | 2020-09-28 | 2023-11-16 | Vor Biopharma Inc. | Compositions and methods for cd6 modification |
US20230364146A1 (en) * | 2020-09-30 | 2023-11-16 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
US20230310508A1 (en) * | 2020-10-16 | 2023-10-05 | The Board Of Trustees Of The Leland Stanford Junior University | Hematopoietic stem cell engraftment with a combination of agents |
US20230414755A1 (en) | 2020-11-13 | 2023-12-28 | Vor Biopharma Inc. | Methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors |
AU2022216614A1 (en) * | 2021-02-05 | 2023-02-23 | Christiana Care Gene Editing Institute, Inc. | Methods of and compositions for reducing gene expression and/or activity |
WO2023283585A2 (fr) | 2021-07-06 | 2023-01-12 | Vor Biopharma Inc. | Oligonucléotides d'inhibition et méthodes d'utilisation de ceux-ci |
CA3228272A1 (fr) | 2021-08-02 | 2023-02-09 | Vor Biopharma Inc. | Compositions et procedes de modification genetique |
CA3236152A1 (fr) * | 2021-11-09 | 2023-05-19 | Vor Biopharma Inc. | Compositions et procedes pour la modification de l'erm2 |
AU2022426854A1 (en) * | 2021-12-31 | 2024-06-13 | The Trustees Of Columbia University In The City Of New York | Bispecific molecules to target the first cell |
WO2023164636A1 (fr) * | 2022-02-25 | 2023-08-31 | Vor Biopharma Inc. | Compositions et procédés pour la modification génétique par réparation dirigée par homologie |
WO2023196816A1 (fr) * | 2022-04-04 | 2023-10-12 | Vor Biopharma Inc. | Compositions et procédés de médiation de l'ingénierie de l'épitope |
WO2023201238A1 (fr) | 2022-04-11 | 2023-10-19 | Vor Biopharma Inc. | Agents de liaison et leurs méthodes d'utilisation |
CN114743598B (zh) * | 2022-06-14 | 2022-09-02 | 湖南大学 | 一种基于信息论检测新冠病毒谱系间重组的方法 |
WO2024015925A2 (fr) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions et méthodes de génération de motif de reconnaissance du proto-espaceur (pam) artificiel |
WO2024073751A1 (fr) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Procédés et compositions pour la modification et l'enrichissement de gènes |
WO2024077145A1 (fr) * | 2022-10-05 | 2024-04-11 | Garuda Therapeutics, Inc. | Cellules souches hématopoïétiques modifiées et leurs descendances |
CN116850210B (zh) * | 2023-01-17 | 2024-05-31 | 武汉大学 | 用于治疗急性髓系白血病的成分和方法 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
JP2752788B2 (ja) | 1989-01-23 | 1998-05-18 | カイロン コーポレイション | 感染および過剰増殖障害の為の組換え療法 |
EP0487587A1 (fr) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
CA2115742A1 (fr) | 1991-08-20 | 1993-03-04 | Ronald G. Crystal | Transfert de genes aux cellules du tractus gastro-intestinal medie par adenovirus |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993010218A1 (fr) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
EP0650370A4 (fr) | 1992-06-08 | 1995-11-22 | Univ California | Procedes et compositions permettant de cibler des tissus specifiques. |
EP0644946A4 (fr) | 1992-06-10 | 1997-03-12 | Us Health | Particules vecteurs resistantes a l'inactivation par le serum humain. |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル. グラハム,フランク | 遺伝子治療のためのアデノウイルスベクター |
DE69434594T2 (de) | 1993-10-25 | 2006-09-21 | Canji, Inc., San Diego | Rekombinante adenoviren-vektor und verfahren zur verwendung |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US5756910A (en) | 1996-08-28 | 1998-05-26 | Burgett, Inc. | Method and apparatus for actuating solenoids in a player piano |
KR100503701B1 (ko) | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
US7968687B2 (en) | 2007-10-19 | 2011-06-28 | Seattle Genetics, Inc. | CD19 binding agents and uses thereof |
RU2635317C2 (ru) | 2009-10-19 | 2017-11-10 | Тристем Трейдинг (Сайпрес) Лимитед | Лечение с применением перепрограммированных зрелых и дифференцированных клеток |
CA2993567C (fr) | 2010-07-21 | 2022-06-28 | Sangamo Biosciences, Inc. | Methodes et compositions destinees a la modification d'un gene recepteurde lymphocyte t |
KR20230133410A (ko) | 2010-12-09 | 2023-09-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
WO2012088461A2 (fr) | 2010-12-23 | 2012-06-28 | Biogen Idec Inc. | Peptides coupleurs et polypeptides les comportant |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
PT2800811T (pt) | 2012-05-25 | 2017-08-17 | Univ California | Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
US9890393B2 (en) | 2013-05-29 | 2018-02-13 | Cellectis | Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system |
EP2833591A1 (fr) | 2013-07-31 | 2015-02-04 | Siemens Aktiengesellschaft | Unité d'interface pour la communication sous-marine de données |
US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
HUE041497T2 (hu) | 2014-02-14 | 2019-05-28 | Cellectis | Immunsejteken és patológiás sejteken egyaránt jelen lévõ antigént célzó génmódosított sejtek immunterápia célra |
DK3569619T3 (da) | 2014-03-19 | 2021-06-14 | Cellectis | Fremgangsmåde til fremstilling af CD123-specifikke CAR T-celler til cancerimmunterapi |
DK3126390T3 (da) | 2014-04-03 | 2020-01-20 | Cellectis | Cd33-specifikke kimære antigenreceptorer til cancerimmunterapi |
EP3129485B2 (fr) | 2014-04-09 | 2022-12-21 | Editas Medicine, Inc. | Méthodes et compositions se rapportant à crispr/cas et destinées au traitement de la fibrose kystique |
CA2945393C (fr) | 2014-04-24 | 2021-03-23 | Board Of Regents, The University Of Texas System | Application de cellules souches pluripotentes induites pour generer des produits de therapie cellulaire adoptive |
WO2015195547A1 (fr) | 2014-06-16 | 2015-12-23 | University Of Washington | Procédés permettant le contrôle du potentiel des cellules souches et l'édition génique dans les cellules souches |
US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
AU2015292811B2 (en) * | 2014-07-21 | 2019-12-19 | Novartis Ag | Treatment of cancer using a CLL-1 chimeric antigen receptor |
CN112481283A (zh) | 2014-07-21 | 2021-03-12 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
EP3878948A1 (fr) | 2014-09-16 | 2021-09-15 | Sangamo Therapeutics, Inc. | Procédés et compositions pour ingénierie génomique à médiation par des nucléases et correction du génome dans des cellules souches hématopoïétiques |
KR101799975B1 (ko) | 2014-10-31 | 2017-11-21 | 에스케이씨하이테크앤마케팅(유) | 액정표시장치용 색순도 향상 및 휘도 보상 필름 및 이를 포함하는 액정표시장치 |
EP3025719B1 (fr) | 2014-11-26 | 2018-09-26 | Miltenyi Biotec GmbH | Combinaison d'immunothérapie de récepteurs reconnaissant un antigène et cellules hématopoïétiques pour le traitement de maladies |
EP3227447B1 (fr) | 2014-12-03 | 2024-04-24 | Agilent Technologies, Inc. | Arn guide comportant des modifications chimiques |
US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
EP3250605A1 (fr) | 2015-01-26 | 2017-12-06 | Cellectis | Récepteurs d'antigènes chimériques (car) spécifiques anti-hsp70 pour une immunothérapie anticancéreuse |
JP6873911B2 (ja) | 2015-04-06 | 2021-05-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 初代細胞において標的核酸の遺伝子調節を誘導するためにインビトロで行う方法 |
SI3280729T1 (sl) * | 2015-04-08 | 2022-09-30 | Novartis Ag | Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR) |
MX2017013321A (es) | 2015-04-22 | 2018-07-06 | Curevac Ag | Composicion que contiene arn para tratamiento de enfermedades tumorales. |
GB201507119D0 (en) | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic Acid Construct |
US20180355318A1 (en) | 2015-04-29 | 2018-12-13 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
WO2016182959A1 (fr) | 2015-05-11 | 2016-11-17 | Editas Medicine, Inc. | Systèmes crispr/cas9 optimisés et procédés d'édition de gènes dans des cellules souches |
TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
WO2017222593A1 (fr) | 2016-06-24 | 2017-12-28 | Icell Gene Therapeutics Llc | Récepteurs d'antigènes chimériques (car), compositions et procédés associés |
CA3001859A1 (fr) | 2015-10-16 | 2017-04-20 | The Trustees Of Columbia University In The City Of New York | Compositions et methodes d'inhibition d'antigenes specifiques a une lignee |
IL294014B1 (en) | 2015-10-23 | 2024-03-01 | Harvard College | Nucleobase editors and their uses |
CA3004053A1 (fr) | 2015-11-04 | 2017-05-11 | The Trustees Of The University Of Pennsylvania | Procedes et compositions pour l'edition de genes dans des cellules souches hematopoietiques |
CA3004743A1 (fr) | 2015-11-24 | 2017-06-01 | Cellerant Therapeutics, Inc. | Anticorps anti-cll-1 humanises |
JP7208010B2 (ja) | 2016-03-29 | 2023-01-18 | ユニバーシティ オブ サザン カリフォルニア | 癌を標的とするキメラ抗原受容体 |
WO2017186718A1 (fr) | 2016-04-25 | 2017-11-02 | Universität Basel | Édition d'allèles et ses applications |
US11787848B2 (en) | 2016-06-08 | 2023-10-17 | Precigen, Inc. | CD33 specific chimeric antigen receptors |
US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
CA3029761A1 (fr) | 2016-07-06 | 2018-01-11 | Cellectis | Edition de genes sequentielle dans des cellules immunitaires primaires |
EP3529262B1 (fr) | 2016-10-21 | 2021-07-21 | INSERM - Institut National de la Santé et de la Recherche Médicale | Procédés et compositions pharmaceutiques permettant de favoriser la réaction des lymphocytes t |
EP4360639A2 (fr) | 2016-11-02 | 2024-05-01 | Universität Basel | Variants de surface cellulaire discernables immunologiquement destinés à être utilisés en thérapie cellulaire |
EP3565895A1 (fr) | 2016-12-30 | 2019-11-13 | Editas Medicine, Inc. | Molécules de guidage synthétiques, compositions et procédés associés |
MX2019010196A (es) | 2017-02-28 | 2019-12-19 | Vor Biopharma Inc | Composiciones y métodos para la inhibición de proteínas específicas del linaje. |
JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
KR20190130613A (ko) | 2017-03-23 | 2019-11-22 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
EA201992546A1 (ru) | 2017-04-24 | 2020-03-06 | Мемориал Слоан Кеттеринг Кэнсер Сентер | Средства на основе антител к cd33 |
WO2019046285A1 (fr) | 2017-08-28 | 2019-03-07 | The Trustees Of Columbia University In The City Of New York | Cellules souches donneuses déficientes en exon 2 de cd33 destinées à être utilisées avec des agents ciblant cd33 |
CA3089843A1 (fr) | 2018-01-30 | 2019-08-08 | Editas Medicine, Inc. | Systemes et procedes de modulation de rearrangements chromosomiques |
CA3087715A1 (fr) | 2018-02-08 | 2019-08-15 | Zymergen Inc. | Edition de genome a l'aide de crispr dans corynebacterium |
TWI669677B (zh) | 2018-03-07 | 2019-08-21 | 光陽工業股份有限公司 | 充電座管理方法、用於充電座管理方法的伺服器及充電座 |
CN113423725A (zh) | 2018-08-28 | 2021-09-21 | Vor生物制药股份有限公司 | 遗传工程化造血干细胞及其用途 |
WO2020095107A1 (fr) | 2018-11-07 | 2020-05-14 | Crispr Therapeutics Ag | Immunothérapie cellulaire anti-cd33 contre le cancer |
AU2020208616A1 (en) | 2019-01-16 | 2021-08-12 | Beam Therapeutics Inc. | Modified immune cells having enhanced anti-neoplasia activity and immunosuppression resistance |
JP2022517618A (ja) | 2019-01-16 | 2022-03-09 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 系統特異的抗原の阻害のための組成物および方法 |
WO2020168122A1 (fr) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Cellules immunitaires modifiées ayant des éditeurs de base d'adénosine désaminase pour modifier une nucléobase dans une séquence cible |
KR20220035877A (ko) * | 2019-05-23 | 2022-03-22 | 보르 바이오파마 인크. | Cd33 변형을 위한 조성물 및 방법 |
EA202191979A1 (ru) | 2019-05-24 | 2021-11-01 | Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк | Композиции и способы ингибирования линиеспецифических антигенов |
WO2021041977A1 (fr) | 2019-08-28 | 2021-03-04 | Vor Biopharma, Inc. | Compositions et procédés pour modification de cd133 |
KR20220047380A (ko) | 2019-08-28 | 2022-04-15 | 보르 바이오파마 인크. | Cll1 변형을 위한 조성물 및 방법 |
WO2023091954A2 (fr) | 2021-11-19 | 2023-05-25 | The Trustees Of The University Of Pennsylvania | Antigène cd45 à spécificité pan-leucocytaire génétiquement modifié pour faciliter une thérapie de lymphocytes t car |
CA3240875A1 (fr) | 2021-12-23 | 2023-06-29 | Stefanie Urlinger | Variants de proteine de surface cellulaire discernable de cd45 destines a etre utilises en therapie cellulaire |
WO2023159136A2 (fr) | 2022-02-18 | 2023-08-24 | Dana-Farber Cancer Institute, Inc. | Modification d'épitope de récepteurs de surface cellulaire |
-
2019
- 2019-08-28 CN CN201980070933.9A patent/CN113423725A/zh active Pending
- 2019-08-28 CA CA3110837A patent/CA3110837A1/fr active Pending
- 2019-08-28 WO PCT/US2019/048662 patent/WO2020047164A1/fr active Application Filing
- 2019-08-28 KR KR1020217009137A patent/KR20220036908A/ko unknown
- 2019-08-28 BR BR112021003670-9A patent/BR112021003670A2/pt unknown
- 2019-08-28 EP EP19766420.4A patent/EP3844187A1/fr active Pending
- 2019-08-28 JP JP2021511635A patent/JP2022520138A/ja active Pending
- 2019-08-28 SG SG11202101994XA patent/SG11202101994XA/en unknown
- 2019-08-28 AU AU2019333104A patent/AU2019333104A1/en active Pending
- 2019-08-28 US US16/554,520 patent/US11389485B2/en active Active
- 2019-08-28 MX MX2021002415A patent/MX2021002415A/es unknown
- 2019-12-03 US US16/701,818 patent/US10925902B2/en active Active
-
2020
- 2020-03-10 US US16/813,958 patent/US20200318071A1/en active Pending
-
2021
- 2021-02-16 US US17/176,610 patent/US11903973B2/en active Active
- 2021-02-25 IL IL281113A patent/IL281113A/en unknown
- 2021-04-05 US US17/222,834 patent/US11559551B2/en active Active
- 2021-04-05 US US17/222,812 patent/US11571445B2/en active Active
- 2021-04-05 US US17/222,855 patent/US11382932B2/en active Active
- 2021-04-05 US US17/222,765 patent/US11464807B2/en active Active
-
2022
- 2022-05-31 US US17/828,513 patent/US20230053285A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220008476A1 (en) | 2022-01-13 |
CN113423725A (zh) | 2021-09-21 |
JP2022520138A (ja) | 2022-03-29 |
US20230053285A1 (en) | 2023-02-16 |
US11571445B2 (en) | 2023-02-07 |
KR20220036908A (ko) | 2022-03-23 |
US20210236559A1 (en) | 2021-08-05 |
US20210220407A1 (en) | 2021-07-22 |
US20200138869A1 (en) | 2020-05-07 |
US20210228641A1 (en) | 2021-07-29 |
US11559551B2 (en) | 2023-01-24 |
EP3844187A1 (fr) | 2021-07-07 |
BR112021003670A2 (pt) | 2021-05-18 |
MX2021002415A (es) | 2021-09-21 |
WO2020047164A1 (fr) | 2020-03-05 |
US10925902B2 (en) | 2021-02-23 |
AU2019333104A1 (en) | 2021-03-25 |
US11382932B2 (en) | 2022-07-12 |
US20210315936A1 (en) | 2021-10-14 |
CA3110837A1 (fr) | 2020-03-05 |
US20200318071A1 (en) | 2020-10-08 |
US20200093865A1 (en) | 2020-03-26 |
US11389485B2 (en) | 2022-07-19 |
US20200338130A9 (en) | 2020-10-29 |
US11903973B2 (en) | 2024-02-20 |
IL281113A (en) | 2021-04-29 |
US11464807B2 (en) | 2022-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281113A (en) | Genetically modified hematopoietic stem cells and their uses | |
IL262772A (en) | Genetically engineered cells and methods for their preparation | |
EP3680338A4 (fr) | Lymphocyte t génétiquement modifié et son application | |
IL277611A (en) | Effector training chamber and its use | |
IL259586A (en) | Genetically modified stem cells and their uses | |
IL289830A (en) | A transgenic effector training cell and its use | |
SG11202004116QA (en) | T cell manufacturing compositions and methods | |
IL287553A (en) | Modified pluripotent cells | |
SG11202011392VA (en) | Genetically engineered cell and application thereof | |
EP3288569A4 (fr) | Cellules souches/progénitrices hématopoïétiques et effectrices non t modifiées, et leurs utilisations | |
IL277673A (en) | Transgenic cells and their uses | |
SG11202111679XA (en) | Engineered cells and uses thereof | |
IL275037A (en) | CRISPR-CAS9-modified CD34+ human hematopoietic stem and progenitor cells and uses thereof | |
IL287874A (en) | Preparations and methods for producing t cells | |
EP3964238A4 (fr) | Cellule immunitaire modifiée ciblant bcma et son utilisation | |
EP3810756A4 (fr) | Lymphocytes t modifiés et leurs utilisations | |
IL287777A (en) | engineered t cells | |
EP4034172A4 (fr) | Cellules souches mésenchymateuses génétiquement modifiées et leurs applications | |
IL255664A0 (en) | Hematopoietic stem cells with enhanced properties | |
SG11202105217RA (en) | Placenta-derived allogeneic car-t cells and uses thereof | |
EP3865571A4 (fr) | Cellules souches mésenchymateuses dérivées de la synoviale et leur utilisation | |
IL290109A (en) | Cells for enhanced immune healing and their uses | |
EP4028024A4 (fr) | Cellules modifiées et leurs utilisations | |
SG10201909544YA (en) | Genetically Modified T Cells And Uses Thereof | |
EP3452581A4 (fr) | 4hpr et son utilisation dans la culture de cellules souches hématopoïétiques |